Welcome to our dedicated page for AtriCure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AtriCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AtriCure's regulatory disclosures and financial reporting.
AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported bona fide gifts totaling 6,000 shares of AtriCure common stock on March 6, 2026, consisting of separate transfers of 5,000 shares and 1,000 shares. No consideration was received for these gifts to his children and sibling, and his directly owned stake was reported as 778,498 shares following the gifts. He also reported indirect holdings held by his children, parents, and sibling, and disclaimed beneficial ownership of those indirect holdings except for his pecuniary interest.
AtriCure, Inc. President and CEO Michael H. Carrel reported equity compensation and related tax withholding transactions in AtriCure common stock. On March 1, 2026, he acquired 68,618 shares through a restricted stock award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date.
He also acquired 101,280 shares upon the vesting and release of a performance share award under the same 2023 plan, after the company performance goals and required service period were met. To cover tax withholding obligations from vesting awards, he transferred 72,777 shares back to the company at $31.26 per share, characterized as a tax-withholding disposition. After these direct transactions, he directly held 784,498 shares of common stock.
In addition, Form 4 reflects 9,310 shares held indirectly by his children and 2,250 shares held indirectly by his parents. A footnote states he disclaims beneficial ownership of these indirectly held securities, except to the extent of his pecuniary interest.
AtriCure, Inc. Chief Marketing & Strategy Officer Justin J. Noznesky reported equity compensation and related tax withholding in company stock. He acquired 27,991 shares through a new restricted stock award and 15,198 shares from a performance share award that vested after meeting company performance and service requirements. To cover tax obligations on vested awards, he transferred 15,586 shares back to the company at a price of $31.26 per share, leaving him with 106,401 shares of common stock held directly.
AtriCure, Inc. Chief Technical Officer Salvatore Privitera reported equity compensation activity involving company common stock. He acquired 30,390 shares on March 1, 2026 through a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares on the same date from the vesting and release of a Performance Share Award under the same plan after company performance goals and service requirements were met. To cover tax withholding obligations related to vesting and release of prior awards, he transferred 13,127 shares back to the company at $31.26 per share, and directly owned 158,048 shares after these transactions.
AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported equity awards and related tax withholding transactions in company common stock. He acquired 30,390 shares through a restricted stock award under the 2023 Stock Incentive Plan, with one third vesting on each of the first, second, and third anniversaries of the grant date. He also acquired 15,198 shares from the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from earlier restricted or performance share vesting, he transferred 15,585 shares back to AtriCure at a price of $31.26 per share.
AtriCure, Inc. reported equity award activity for Chief Financial Officer Angela L. Wirick. On March 1, 2026, she acquired 39,987 shares of common stock through a restricted stock award under the 2023 Stock Incentive Plan, which will vest in three equal annual installments. She also acquired 23,101 shares from the vesting of a performance share award after company performance goals and service requirements were met. To cover tax withholding from these vestings, she disposed of 22,965 shares back to the company at $31.26 per share, leaving her with 204,893 directly owned shares of common stock.
AtriCure, Inc. Chief Operating Officer Douglas J. Seith reported equity compensation and related tax withholding in company stock. On March 1, 2026, he received 42,386 shares of common stock as a restricted stock award that vests in three equal annual installments. He also acquired 25,532 shares through the vesting and release of a performance share award after company performance goals and service requirements were met. To cover tax obligations from these vestings, he transferred 22,948 shares back to the company at $31.26 per share. Following these transactions, he directly owned 229,340 shares of AtriCure common stock.
AtriCure, Inc.’s Chief Legal Officer, Karl S. Dahlquist, reported equity compensation and related tax withholding transactions in company common stock. He acquired 27,991 shares through a restricted stock award and 15,198 shares through the vesting of a performance share award under the 2023 Stock Incentive Plan.
According to the filing, one third of the restricted stock will vest on each of the first, second, and third anniversaries of the grant date. The performance share award vested after company performance goals and service requirements were met.
Dahlquist also disposed of 15,687 shares at a price of $31.26 per share by transferring them back to the company to satisfy tax withholding obligations arising from the vesting and release of earlier restricted stock or performance share awards.
AtriCure, Inc. develops and sells medical devices for surgical treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post‑operative pain control. Its products are used in open‑heart, minimally invasive, and hybrid procedures, and are sold mainly through a direct sales force in the U.S. and key international markets.
The company’s portfolio includes Isolator Synergy and EnCompass RF clamps, EPi‑Sense hybrid ablation systems, AtriClip LAA exclusion devices, and cryoICE/cryoSPHERE/cryoXT probes for Cryo Nerve Block pain therapy. AtriCure supports these products with extensive clinical trials such as CONVERGE, LeAAPS, BoxX‑NoAF, HEAL‑IST and ICE‑AFIB, and invests heavily in physician training and education.
AtriCure highlights large underpenetrated markets in Afib surgery, LAA exclusion, and non‑opioid pain management, while noting competitive, regulatory, reimbursement and execution risks. As of June 30, 2025, non‑affiliate common stock held a market value of about $1,571.5 million, with 49,809,901 shares outstanding as of February 12, 2026.
AtriCure, Inc. reported strong growth for the fourth quarter and full year 2025 while moving toward sustained profitability. Fourth quarter 2025 revenue was $140.5 million, up 13.1% year over year, with net income of $1.8 million and adjusted EBITDA of $19.9 million. Full year 2025 revenue reached $534.5 million, an increase of 14.9%, and gross margin improved to 75.0%. The company narrowed its net loss to $11.4 million while nearly doubling adjusted EBITDA to $61.8 million. Management projects 2026 revenue of $600–$610 million, full year positive net income, and adjusted EBITDA of $80–$82 million, with expected adjusted EPS between $0.09 and $0.15 and GAAP EPS between $0.00 and $0.04.